Drug Trial Radar · NCT00957996
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
Last checked: Nov 20, 2026Latest source record: Feb 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
234
Actual
Start
Oct 2009
Primary completion
Oct 2010
Study completion Aug 2011
Sponsor
- Lead sponsor
- BioCryst PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- Department of Health and Human Services
- First posted
- Aug 13, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, open-label, randomized study of the antiviral activity, safety, and tolerability of intravenous Peramivir in hospitalized subjects with confirmed or suspected influenza infection.
Conditions
- Seasonal Influenza
- Cough
- Sore Throat
- Nasal Congestion
- Myalgia
- Headache
- Fatigue
Interventions
PeramivirDrug
300 mg twice daily
PeramivirDrug
600 mg once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Influenza Virus Titer (48 Hours)Time frame: Baseline and 48 hours
Locations
110 sites in 6 countries. Site status is shown where the registry gives one.
Site not named
Dothan, Alabama
Site not named
Mobile, Alabama
Site not named
Jonesboro, Arkansas
Site not named
Little Rock, Arkansas
Site not named
Fountain Valley, California
Site not named
Harbor City, California
Site not named
La Mesa, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Modesto, California
Site not named
Oceanside, California
Site not named
Orange, California
Site not named
Palo Alto, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
San Francisco, California
Site not named
San Jose, California
Site not named
Denver, Colorado
Site not named
Wheat Ridge, Colorado
Site not named
Washington D.C., District of Columbia
Site not named
Brandon, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Gainsville, Florida
Site not named
Ocoee, Florida
Site not named
Orlando, Florida
Site not named
West Palm Beach, Florida
Site not named
Columbus, Georgia
Site not named
Decatur, Georgia
Site not named
Honolulu, Hawaii
Site not named
Idaho Falls, Idaho
Site not named
Chicago, Illinois
Site not named
Rock Island, Illinois
Site not named
Springfield, Illinois
Site not named
Indianapolis, Indiana
Site not named
South Bend, Indiana
Site not named
Topeka, Kansas
Site not named
Hazard, Kentucky
Site not named
Natchitoches, Louisiana
Site not named
Shreveport, Louisiana
Site not named
Baltimore, Maryland
Showing 40 of 110 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.